ReviewJournal of immunology (Baltimore, Md. : 1950)2010
Tumor-induced disruption of proximal TCR-mediated signal transduction in tumor-infiltrating CD8+ lymphocytes inactivates antitumor effector phase.
Review in Journal of immunology (Baltimore, Md. : 1950), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 40 citations in OpenAlex.
- Review
- DOK1 and DOK2 regulate CD8 T cell signaling and memory formation without affecting tumor cell killing.Scientific reports · 2024Article
- Optimal combination treatment regimens of vaccine and radiotherapy augment tumor-bearing host immunity.Communications biology · 2021Article
- PD-1 suppresses the maintenance of cell couples between cytotoxic T cells and target tumor cells within the tumor.Science signaling · 2020Article
- Exosomes Associated with Human Ovarian Tumors Harbor a Reversible Checkpoint of T-cell Responses.Cancer immunology research · 2018Article
- The dual role of complement in cancer and its implication in anti-tumor therapy.Annals of translational medicine · 2016Review
- The application of the fibroblast activation protein α-targeted immunotherapy strategy.Oncotarget · 2016Review
- A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors.Cancer research · 2016Article
- Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2016Article
- Cish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance.The Journal of experimental medicine · 2015Article
- Extracellular Vesicles Present in Human Ovarian Tumor Microenvironments Induce a Phosphatidylserine-Dependent Arrest in the T-cell Signaling Cascade.Cancer immunology research · 2015Article
- Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors.Clinical cancer research : an official journal of the American Association for Cancer Research · 2014Article
- Level of circulating PD-L1 expression in patients with advanced gastric cancer and its clinical implications.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2014Article
- Giving oncolytic vaccinia virus more BiTE.Molecular therapy : the journal of the American Society of Gene Therapy · 2014Article
- PD-1 targeting in cancer immunotherapy.Cancer · 2013Article
- Positive and negative influence of the matrix architecture on antitumor immune surveillance.Cellular and molecular life sciences : CMLS · 2013Review
- Enhanced function of cytotoxic T lymphocytes induced by dendritic cells modified with truncated PSMA and 4-1BBL.Human vaccines & immunotherapeutics · 2013Article
- Changes in ovarian tumor cell number, tumor vasculature, and T cell function monitored in vivo using a novel xenograft model.Cancer immunity · 2013Article
- T-cell modulatory properties of CD5 and its role in antitumor immune responses.Oncoimmunology · 2013Article
- The CD3-zeta chimeric antigen receptor overcomes TCR Hypo-responsiveness of human terminal late-stage T cells.PloS one · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
The presence in cancer tissue of Ag-specific, activated tumor infiltrating CD8(+) T cells proves that tumors express Ags capable of eliciting immune response. Therefore, in general, tumor escape from immune-mediated clearance is not attributable to immunological ignorance. However, tumor-infiltrating lymphocytes are defective in effector phase function, demonstrating tumor-induced immune suppression that likely underlies tumor escape. Since exocytosis of lytic granules is dependent upon TCR-mediated signal transduction, it is a reasonable contention that tumors may induce defective signal transduction in tumor infiltrating T cells. In this review, we consider the biochemical basis for antitumor T cell dysfunction, focusing on the role of inhibitory signaling receptors in restricting TCR-mediated signaling in tumor-infiltrating lymphocytes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.